This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berkowitz, S. D. Search for Related Content PubMed PubMed Citation Articles by Berkowitz, S. D.

Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization

Scott D. Berkowitz, MD, FACP^a, David C. Sane, MD^*, Kristina N. Sigmon, MA^a, Jane H. Shavender, BA^a, Robert A. Harrington, MD, FACC^a, James E. Tcheng, MD, FACC^a, Eric J. Topol, MD, FACC, Robert M. Califf, MD, FACC^a for the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group

^a Divisions of Hematology/Coagulation and Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
^* Section of Cardiology, Wake Forest University, Winston-Salem, North Carolina, USA
Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA

View larger version (14K): [in a new window]   Figure 1 The probability (with 95% confidence intervals) of developing thrombocytopenia over the observed range of baseline platelet count (A), age (B) and weight (C).

View larger version (15K): [in a new window]   Figure 2 Cumulative distribution function plot depicting the cumulative development of thrombocytopenia over time in patients receiving abciximab as compared with those receiving placebo.